Federated Hermes: Revolutionizing Pharma Research with Real-World Data Access and Tax-Free Dividends
- Federated Hermes Premier Municipal Income Fund announces a tax-free dividend of $0.0450 per share for investors.
- The fund emphasizes Federated Hermes’ commitment to providing tax-efficient investment solutions for a diverse clientele.
- Analyst ratings for Federated Hermes vary, reflecting the complexities and risks in the current market environment.
Unlocking Real-World Data Access: datma’s Federated Biomarker Explorer Revolutionizes Pharmaceutical Research
In a significant move for the pharmaceutical and life sciences sectors, datma announces the launch of the Federated Biomarker Explorer, a pioneering application designed to facilitate real-world data access. This innovative tool enables pharmaceutical teams to evaluate biomarker coverage within datma's extensive federated network, streamlining the data sourcing process. By allowing users to assess whether specific datasets encompass the necessary patient populations, the Explorer eliminates the need for cumbersome data integration and procurement processes. This advancement is particularly crucial in an industry increasingly reliant on timely and accurate data for drug development and market access strategies.
The Federated Biomarker Explorer enhances efficiency by providing aggregate, cohort-level visibility into biomarker presence. Users can filter information based on various clinical and demographic attributes, which significantly reduces the time and resources typically spent on exploratory data discussions. Robin Edison, VP of Product at datma, emphasizes that the tool allows for quick assessments, thereby accelerating the pace at which pharmaceutical teams can move from data exploration to actionable insights. This capability is vital for companies aiming to leverage real-world data to inform their research and development pipelines without incurring additional time, budget, or legal costs.
Noah Nasser, CEO of datma, underscores the application’s role in minimizing barriers to real-world data collaboration. The Explorer not only provides immediate usability and visibility but also supports federated analysis across both internal and external datasets through datma.FED, enhancing existing data with targeted real-world cohorts. This development aligns with the broader industry trend of integrating real-world evidence into drug development processes, positioning datma as a leader in facilitating efficient data collaboration. The Federated Biomarker Explorer is now available to pharmaceutical and life sciences teams, marking a significant step forward in optimizing data access and analysis.
In parallel, Federated Hermes Premier Municipal Income Fund announces a tax-free dividend aimed at providing investors with current income exempt from federal income tax and alternative minimum tax (AMT). The fund declares a dividend of $0.0450 per share, underscoring Federated Hermes’ commitment to tax-efficient investment solutions. This announcement reflects the company’s strategic focus on delivering diverse investment opportunities to a broad clientele of institutions and intermediaries globally.
Moreover, analyst ratings for Federated Hermes reveal a spectrum of opinions ranging from optimistic to cautious, reflecting the complexities of the current market environment. These insights can guide investors in making informed decisions regarding their investment positions in Federated Hermes, highlighting the need to consider both potential growth opportunities and risks as the company navigates through evolving economic dynamics.